Chinese Authorities To Contain Number Of New Pharmaceutical Companies
This article was originally published in PharmAsia News
In a recent proposal to expedite the restructuring of China's healthcare industry, the State FDA, the Ministry of Industry and Information Technology and the Ministry of Health have requested that the country's regional FDA offices raise technology requirements during drug review and approval to curb the number of new pharmaceutical companies
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.